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Post-acute care and secondary prevention after
ischaemic stroke
K S McArthur clinical research fellow, T J Quinn lecturer in geriatric medicine, P Higgins clinical
research fellow, P Langhorne professor of stroke care
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary, Glasgow G11 6NT, UK
In the first part of this two part review (BMJ 2011;342:d1938)
we discussed acute diagnosis and management of
cerebrovascular events. Much of the focus of recent research,
public health initiatives, and health policy has been around acute
and hyperacute management of stroke. However, important
goals of stroke care are to maximise functional recovery and
prevent recurrent events. Here we draw on evidence from
randomised trials and meta-analyses to discuss models of care,
rehabilitation, and secondary prevention in stroke.
An important aspect of post-acute stroke care is rehabilitation.
Rehabilitation research remains a “young” science, although an
evidence base is emerging. As we make progress in this field,
we need a common language to describe this important
intervention. In the box we offer our own definition of stroke
rehabilitation, although others may offer differing suggestions.
Many questions remain unanswered regarding timing, optimal
components, and frequency and intensity of rehabilitation.
Further discussion of rehabilitation as a concept or rehabilitation
theory specific to stroke is beyond the scope of this article, but
recent high quality publications on the subject are available.w1
w2
This review will focus on the early period after stroke. Effective
early intervention may affect longer term outcomes,w3 with
combined analysis of three UK stroke cohorts (n=7710 patients)
showing that long term survival is predicted by functional
outcome at six months.w4Most interventional research in stroke
has focused on these first days to months after a stroke event,
whereas health needs and management of stroke survivors
outside of this period has received little attention. This is
unfortunate in a cohort with high incidence of residual disability
and often complex comorbidity, and more work is needed to
inform practice and policy.
How should I assess a patient who has
survived a stroke?
Assessment in the first days after stroke will guide subsequent
management. The aims are to ascertain the pathology and
mechanism of the stroke, identify post-stroke complications,
and describe initial impairments.
“Acute” brain imaging was discussed in the first part of this
review and will not be covered here. Further investigation to
identify a possible origin and guide treatment may include
assessment of extracranial carotid arteries, heart structure, or
arrhythmia. The potential deleterious effects of deranged
“physiology” (temperature, blood pressure, glycaemic control)
were also discussed in the previous review. Evidence for
intervention remains inconclusive, although routine frequent
monitoring of these parameters in the first 72 hours remains
usual practice.
Regular (at least daily) assessments of neurological function
are important in planning effective ongoing medical care and
early rehabilitation. Longitudinal cohort studies suggest that
early measures of disability predict longer term outcomes.w5 In
the first days after stroke, neurological findings are dynamic.
The National Institutes of Health Stroke Scalew6 and Glasgow
Coma Scalew7 are often used initially as global measures.
Deterioration suggests that further investigation is needed to
exclude hemispheric oedema or haemorrhage. Therapists will
plan intervention on the basis of early functional assessments
of visuospatial awareness, sitting balance, and mobility. Later
the focus of assessment will move to activity measures, using
validated tools such as the Barthel indexw8 or modified Rankin
scale.w9
Post-stroke dysphagia is common—occurring in up to half of
patients—and is associated with an increased risk of aspiration
pneumonia and poor outcomes related to disability, increased
length of stay, and death.w10Meanwhile, withholding oral intake
presents a risk of dehydration and malnutrition. Routine early
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Summary points
The management of stroke patients within dedicated stroke units prevents disability and saves lives for patients of all
ages, with all types and severities of stroke
Venous thromboembolism prophylaxis with compression stockings is not routinely recommended andmay cause harm.
Early mobilisation and physiotherapy are recommended by guidelines and appear to be safe, although definitive data
on efficacy are awaited
Medical complications after stroke are common and affect functional outcomes as well as mortality; infection, delirium,
and dysphagia are potentially treatable
Early artificial feeding with percutaneous gastrostomy tube has not shown longer term benefit for stroke survivors with
impaired swallow and nasogastric feeding is recommended for initial management
Secondary prevention with anti-hypertensive, anti-thrombotic, and lipid lowering drugs reduces likelihood of recurrent
stroke
Stroke rehabilitation—a working definition
Stroke rehabilitation is not (usually) a single intervention; rather, it is an active process with a holistic, individualised focus.
It usually involves teams made up of various professionals, the patient, and other relevant parties (such as carers), all with
a final common goal of enhancing functioning to enable patients and carers to live their lives to the fullest potential.
Based on Quinn and Langhorne, Oxford Desk Reference Geriatric Medicine, 2011.
Sources and selection criteria
This review is based on the authors’ clinical and research experience and informed by a search of published literature.
Electronic databases (Medline and Embase) were searched from inception to December 2010 inclusive, using truncated
keywords: “stroke or cerebrovascular”; “rehabilitation”; “prevention”. In addition key reference works, national and international
guidelines, and journals were searched for relevant papers. Particular attention was given to large randomised controlled
trials, systematic reviews, and meta-analyses. The intention was not to offer comprehensive systematic review but to give
a narrative overview and critique of published work.
assessment of swallow is recommended by national guidelines.1 2
Assessment should be frequent; most patients with early
dysphagia will regain swallow by the second week.w11A bedside
water swallow test (where a patient is asked to swallow a small
volume of water) is a reasonable screening testw12 and will
determine the need for formal assessment of swallowing. Such
assessment is performed by speech and language therapists and
is often complemented by functional imaging, such as video
fluoroscopy.
What kind of care should be delivered in
hospital?
Evidence of benefit of stroke units
In the past two decades many single centre trials highlighted
poor outcomes associated with generic care compared with care
undertaken in dedicated stroke units. A Cochrane review from
2007 of 31 trials (n=6936 participants) confirmed the benefits
of organised specialist care for patients with stroke.3 Compared
with general wards, the number needed to treat in a specialist
unit was 22 to prevent one death and 16 to prevent one patient
losing their independence, which compares favourably with
other interventions for stroke (tables 1 and 2). The benefits of
being cared for in a stroke unit extend to all ages, subtypes, and
severities of stroke, and studies with longer follow-up suggest
that benefits endure.w3, w13 An economic analysis alongside a
randomised trial found that care in a dedicated stroke unit was
cost effective.w14 The evidence clearly suggests that such a
service should be available for all patients who experience a
stroke.
What makes a stroke unit?
To tease out the components of an effective complex
intervention can be a challenge.4 Although a systematic review
has highlighted the importance of monitoring and treating
complications,5 traditional medical input is unlikely to be the
sole factor contributing to the success of a stroke unit. A survey
of recent trials suggests that an essential component is the
multidisciplinary team with a specialist interest in stroke, who
provide an organised package of care coordinated through
regular team meetings. The setting and achievement of goals
requires collaboration of medical, nursing, and therapy staff in
hospital and in the community and should be guided by the
patient and carers.
Within this generic description, care in the stroke unit varies,
and the definition of the “ideal” stroke unit is flexible. Many
countries are pushing towards direct admission to stroke units,
although other models of care were included in the Cochrane
review3Although the benefits of immediate admission to stroke
care seem intuitive (early specialist input, prompt intervention),
robust supporting evidence is not available.
Recent research has focused on opening the “black box” of
stroke unit care. The individual components that have been
investigated and shown to be beneficial, potentially beneficial,
or of uncertain benefit are summarised in the figure. Robust
evidence is emerging for specific areas of stroke care and those
with recent data have been selected for further discussion here.
Prevention of venous thrombosis
Stroke survivors are at substantially increased risk of developing
deep vein thrombosis because they are immobile and often
dehydrated.w15 w16 An open label randomised trial compared
prophylactic low molecular weight heparin and unfractionated
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heparin for the prevention of venous thromboembolism after
acute ischaemic stroke, and showed that enoxaparin was
effective and relatively safe in reducing ultrasound detected
deep vein thrombosis, although whether a clinical benefit exists
is uncertain.6 The trial did not compare heparin with placebo.
The available data do not allow definitive advice on use of
heparin, and further research about targeting this treatment to
those at greatest risk is needed.w17
The recently published Clots in Legs Or sTockings after Stroke
(CLOTS) trials provided pragmatic data about use of
thromboembolic prevention stockings. Compared with no
stockings, thigh or knee length stockings did not significantly
reduce the risk of deep vein thrombosis.7 There was a trend
towards increased deep vein thrombosis in the group that used
knee length stockings, and substantial rates of skin complications
were reported with both types of stocking.8Although the clinical
implications of the CLOTS trials continue to be debated, routine
use of stockings cannot be recommended on the basis of current
evidence.
Feeding patients
The Feed Or Ordinary Diet (FOOD) family of large randomised
trials assessed different aspects of nutrition after stroke. The
first assessed routine oral supplementation in stroke survivors
with intact swallow (n=4023)9 compared with normal diet, and
found that routine supplementation did not improve outcomes
or reduce complications (absolute risk reduction in mortality
0.7%, 95% confidence interval -1.4 to 2.7; overall mortality
rates were 12% in groups receiving supplements and 13% in
those with no supplements). However, these findings do not
preclude the targeted use of supplements where there is evidence
or risk of malnutrition. The second and third studies examined
the relative merits of early feeding by nasogastric tube (n=859)
or percutaneous gastrostomy tube (n=321) after stroke.10 Early
tube feeding was associated with a trend towards reduction in
risk of death (absolute risk reduction 5.8%, 95% confidence
interval -0.8 to 12.5). By contrast, early feeding by percutaneous
gastrostomy tube was associated with a trend towards increased
risk of death or poor outcome (7.8%, 0 to 15.5). This finding is
partly explained by the severity of stroke that requires artificial
feeding; however, use of percutaneous gastrostomy tube is not
a benign intervention and has associated short and longer term
morbidity.w18 w19 Patients’ preferences and quality of life after
percutaneous gastrostomy tube feeding are poorly researched,
but available data suggest no improvement in quality of life.w20
Based on these findings, early placement of percutaneous
gastrostomy tubes is not advisable. Options for long term feeding
are limited and percutaneous gastrostomy tube feeding may
have a role in selected individuals, after discussion with the
patient, relatives, and multidisciplinary team.
Mobilisation: how soon?
UK guidelines recommend by consensus that patients should
sit out of their bed and become mobile as soon as their clinical
condition permits. It seems intuitive that early mobilisation
should reduce the sedentary complications of stroke (muscle
wasting, thrombosis, pressure sores, hypostatic pneumonia) but
there is limited evidence to support the practice. A Very Early
Rehabilitation Trial (AVERT) is currently assessing the value
of early mobilisation in a multicentre randomised controlled
trial. Fears that early mobilisation may be harmful seem to be
unfounded; initial results suggest that mobilisation within the
first day is well tolerated and may prevent complications.w21
Facilitating discharge
Patients and their carers have reported feeling afraid and
unsupported at the time of discharge, and an interview
questionnaire study has shown that inadequate provision of
information is associated with poor satisfaction for stroke
survivors and carers.w22 However, a recent systematic review
andmeta-analysis of randomised controlled trials that evaluated
dedicated stroke liaison services found no evidence of efficacy
compared with standard care in improvingmeasures of extended
activities of daily living and patient/carer subjective health
status.11
A prolonged inpatient stay is costly, and services are
increasingly encouraged to facilitate an early return to the
community. A 2005 meta-analysis of data from studies of early
supported discharge concluded that a multidisciplinary,
appropriately trained early supported discharge service can
significantly reduce days in bed for stroke survivors with mild
to moderate impairments, with no corresponding increase in
readmission or morbidity12 and with overall cost benefit.w23
In view of the sound evidence base for stroke unit admission
and early supported discharge for selected patients, it is
unfortunate that recent UK audit data suggest continuing
inequity of access to these services. It seems reasonable to
speculate that universal delivery of evidence based post-acute
stroke care would, through its impact on disability, result in
lower incidence of stroke survivors needing institutional or
additional domiciliary care, and ultimately would offer cost
savings.
Antithrombotic following ischaemic stroke
The preventive efficacy of aspirin, clopidogrel, dipyridamole,
and the coumarin anticoagulant warfarin have been evaluated,
as monotherapy and (because of their differing mechanisms of
action) in combination. (table 3)
Formonotherapy, a largemeta-analysis showed a 15% reduction
in risk of vascular events with aspirin compared with placebo
over two years.w41 A randomised trial showed a modest benefit
of clopidogrel over aspirin in reducing vascular events, in a
population that included patients with stroke related disease.w42
Dipyridamole has similar efficacy to aspirin but is associated
with frequent adverse effects, mainly headache and
gastrointestinal disturbance.w43
Ameta-analysis of trials showed that the combination of aspirin
and modified release dipyridamole is better than aspirin
monotherapy15 and equivalent to clopidogrel monotherapy for
stroke prevention.16Dipyridamole has little effect on non-stroke
vascular events, suggesting that it has specific cerebrovascular
efficacy. Combinations of aspirin and clopidogrel have been
studied in two large trials, both of which found that any
reduction in vascular events was outweighed by increased
haemorrhagic adverse events.17 18 Bleeding rates with aspirin
and clopidogrel in combination are similar to those with warfarin
and the risks should not be underestimated.w44 Some patients at
high risk may benefit from short term combination antiplatelet
therapy; in a trial of 107 patients with carotid stenosis and active
embolisation, dual antiplatelet therapy was associated with
reduced embolic burden and a trend towards reduced events.19
Interpretation of antiplatelet trial data to guide clinical practice
is complex. While current Scottish guidance suggests aspirin
and modified release dipyridamole as routine therapy, the most
recent National Institute for Health and Clinical Excellence
assessment recommends clopidogrel because of its better
tolerability. For example, in one large study, premature
discontinuation of aspirin plus extended release dipyridamole
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was substantially higher than with clopidogrel (1650 patients
[16.4%] versus 1069 [10.6%], P<0.001).w45
Warfarin has been studied in patients with sinus rhythm and
with atrial fibrillation. For those with sinus rhythm a series of
trials has shown that any benefit of anticoagulation is
outweighed by an increased risk of bleeding for all levels of
stroke risk.20 Patients with cardioembolic stroke face a
particularly high risk of recurrence. Stroke risk in patients with
atrial fibrillation can be stratified and scoring systems have been
developed (webfigure) to guide choice of therapy. Regardless
of the scoring system used, where a patient has sustained a
cerebrovascular event, the risk of subsequent stroke is
sufficiently high to warrant the use of warfarin where possible.
In patients with atrial fibrillation treated with aspirin, the risk
of first stroke is 2.7% per annum and risk of recurrent stroke
10%. Treatment with warfarin has been shown to reduce these
risks to 1.5% and 4% respectively in a meta-analysis.21 A
Cochrane review confirmed the benefit of warfarin compared
with aspirin (odds ratio 0.49, 95% confidence interval 0.33 to
0.72), calculating 60 fewer annual recurrent strokes per 1000
patients treated with warfarin.22
The timing of anticoagulant initiation after stroke is unclear.
Large infarcts or major clinical deficits raise concerns about
haemorrhage and decisions should be based on individual
patients’ characteristics. Some guidelines suggest starting
therapy within 14 days. Although this is a reasonable general
approach, patients must be considered individually—these data
are from a single study (n=225) where less than half of the
participants started warfarin within the first two weeks.w46
Despite its clear efficacy, clinicians may avoid warfarin, perhaps
fearing risk of haemorrhage and problems with monitoring and
adherence. Risk of warfarin related bleeding complications can
also be stratified (webfigure). Oral anticoagulation shows the
classic “inverse care law”, with those at greatest risk of stroke
least likely to receive therapy. For example, older cohorts have
a raised prevalence of atrial fibrillation and greater risk of stroke,
yet underuse of anticoagulation remains prevalent,w47 despite
compelling evidence from a UK general practice based study
that showed the efficacy and relative safety of warfarin in
selected older patients.23Anew generation of oral anticoagulants
are showing promise in clinical trials and may widen delivery
of anticoagulation.24
How are common complications treated
after stroke?
Common complications in the longer term after stroke include
delirium, infection, depression, post-stroke pain, falls, and
incontinence. All these complications may be underdiagnosed
and have little evidence available to guide treatment, although
they affect rehabilitation negatively and are strong predictors
of poor functional outcome and mortality.13w24
Delirium is a common complication after stroke; observational
studies suggest an incidence of around 13-48% of patientsw25
but assessment is complicated by the prevalence of concomitant
communication deficits and dementia. The stroke insult itself
may cause delirium, but infection is often a precipitant. The rate
of nosocomial infection after stroke can be as high as 30%.w26
Pneumonia and urinary tract infections remain themost common
infections, although they may be prevented by regular
assessment of swallow and avoidance of urinary catheters.w27
Post-stroke depression has been reported in a third of patientsw28
but the validity of estimates is questionable because the best
method for screening or diagnosis is uncertain. A systematic
review found that drug treatment can improvemood and reduce
excessive emotions but had frequent side effects, and there was
no robust evidence of benefit for non-drug treatments.w29
Post-stroke pain is multifactorial in origin, with important
components including neuropathic pain and spasticity.
Treatments that have been assessed for specific causes of pain
include tricyclics, anticonvulsants, and botulinum toxin;
evidence of their benefit is emerging but high costs and side
effects may limit their widespread use. Shoulder pain in a paretic
limb is increasingly recognised.w30 Robust evidence to guide
management of such pain is lacking,w31 although suggestions
are available for best practice in assessment and intervention.w32
Falls are common both in the acute setting and in the longer
term after stroke.w33 Putative risk factors include dementia,
depression, polypharmacy, and sensory impairment.w34 The
incidence of fracture is substantial (twofold increase in risk of
hip/femur fracturew35) in the post-stroke population.w36
Interventions to reduce risk of fracture are extrapolated from
studies in older people that were not limited to those who had
had a stroke; no stroke specific data are available. Preventive
treatments may include bisphosphonates and preparations of
calcium vitamin D, and multidisciplinary prevention packages
that focus on personal and environmental factors. A recent
systematic review and meta-analysis has highlighted the need
for future randomised controlled trials in this area; it found
evidence only to support vitamin D supplementation in a female
population in hospital.w37
Prevalence of urinary incontinence is estimated at 40-60% in
an acute stroke population, with 15% remaining incontinent at
one year.w38Causes may include abnormalities of normal central
control of voiding, lower urinary tract infection, and functional
incontinence. A Cochrane review evaluated the limited evidence
on physical interventions such as bladder retraining and pelvic
floor exercises, and drug treatment, which may have a role in
selected patients.w39
What measures help to prevent another
stroke?
The risk of recurrent vascular events after a stroke or TIA is
substantial. Recurrent stroke has been reported in 17.3% of
patients after TIA and 18.5% after minor stroke at three
months.w40National guidelines suggest that secondary preventive
strategies be commenced early and continue indefinitely.1 14
Management of carotid disease
International guidelines recommend that survivors of stroke are
investigated for large artery atherosclerosis, particularly
ipsilateral extracranial carotid artery disease.25 Where imaging
confirms stenotic carotid disease, patients with non-disabling
events may benefit from surgical carotid endarterectomy. As a
general rule, all patients with greater than 50% symptomatic
internal carotid stenosis should be considered for intervention
in the setting of a neurovascular multidisciplinary team. The
benefits of intervention vary with degree of stenosis and time
since event. A pooled analysis of data from randomised
controlled trials of endarterectomy for symptomatic carotid
stenosis (6092 patients) showed that for severe symptomatic
stenosis (>70%), surgery afforded a 15.6% absolute risk
reduction in ipsilateral ischaemic stroke over five years versus
medical treatment alone, with a smaller 4.5% absolute risk
reduction for moderate (50-69%) stenosis.26 Surgery carried no
benefit in less severe disease or in cases of complete occlusion.
Greater benefit is seen with early surgery. Treatment within two
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weeks of symptoms afforded an absolute risk reduction of 23%,
by comparison with absolute risk reduction of 7.4% for those
treated after 12 weeks. In order to prevent one ipsilateral stroke
at five years, the number needed to treat is five within twoweeks
and 125 if surgery is delayed beyond 12 weeks.27 The benefits
of early treatment are particularly pronounced in women, where
significant efficacy of revascularisation is seen only in the first
two weeks.w48
Percutaneous stenting of carotid vessels has been proposed as
a less invasive method of revascularisation, but studies have
failed to show that stenting has the long term benefits of
traditional endarterectomy. Risk and benefit may change as
technical expertise develops but present guidelines do not
recommend stenting outside clinical trials.28
How to manage hypertension
Management of hypertension in the acute phase was discussed
in the first part of this review. Long term management of
hypertension significantly reduces the risk of recurrent events.
Meta-analysis of secondary prevention trials showed a 24%
reduced odds of recurrent stroke with antihypertensive treatment
(odds ratio 0.76, 95% confidence interval 0.63-0.92; absolute
rate of recurrent stroke 10% ).w49 Risk reduction is related to
change in blood pressure and substantial benefit is seen even
with a modest change in pressure. An overview of published
reviews including more than 188 000 participants, showed that
for each 10 mm Hg reduction in systolic pressure, risk was
reduced by one third. This finding was consistent across sex,
region, and stroke subtypes.29
Evidence clearly indicates that all patients should be considered
for antihypertensive therapy to prevent recurrent stroke. UK
guidelines suggest a target blood pressure of 130/80 mm Hg;
for most patients this will require at least two agents, one of
which should be a diuretic.28
The large PROGRESS trial has been pivotal in guiding
post-stroke blood pressure management.30 Treatment with the
ACE inhibitor perindopril, in combination with the thiazide
indapamide, showed a 26% reduced risk of stroke (95%
confidence interval 16% to 34%) compared with placebo.
Patients were considered for inclusion regardless of baseline
blood pressure and benefits were seen even in those traditionally
defined as normotensive.
Choice of antihypertensive agent may be important. In one
pooled analysis the strongest evidence was for diuretic based
therapy (odds ratio 0.63, 95% confidence interval 0.55 to 0.73).
w50 Theoretical benefits of angiotensin receptor antagonists in
stroke prevention have not been supported by large scale trials.w51
w52
Treating high cholesterol, diabetes and
lifestyle risks
The stroke related benefits of statin treatment were originally
described through sub-analyses data relating to ischaemic heart
disease. In a large pooled analysis of data from coronary disease
trials, statin treatment significantly reduced the risk of incident
stroke (odds ratio 0.79, 95% confidence interval 0.73 to 0.85).31
The SPARCL trial (n=4731), a stroke specific placebo controlled
study of statins (atorvastatin 80 mg), showed a reduction in
incident ischaemic stroke (number needed to treat 45 over five
years) and other vascular events, but a rise in incident
haemorrhagic stroke (number needed to harm 107 over five
years).w53 UK guidelines recommend treating to a total
cholesterol of less than 4.0 mmol/L and LDL less than 2.0
mmol/L.28 Statins are not recommended after intracerebral
haemorrhage unless indicated for other vascular disease.
Observational studies have suggested a high prevalence of occult
diabetes in stroke cohorts, which suggests that screening for
diabetes may be useful after stroke. Although diabetes is an
important risk factor for vascular events, no specific guidelines
are available for optimal therapy in patients with stroke. A
subgroup analysis of the PROactive trial described a reduced
incidence of stroke with pioglitazone in selected patients32 but
the findings must be interpreted in the light of other risks
associated with thiazolidinediones. Several large randomised
controlled trials have compared aggresive glycaemic control
with standard therapy. Although these studies were not designed
to measure stroke outcomes, they did not show reduced
incidence of stroke with tight glycaemic control.w54
No data from randomised controlled trials are available to guide
lifestyle modification in patients with stroke. Compelling
observational data support cessation of smoking.w55 The relation
between alcohol and cerebrovascular risk is controversial.
Meta-analysis of 84 observational studies described a “J-shaped
curve” where lowest vascular risk was associated with modest
intake, but specific stroke risk was increased at intakes of more
than one unit daily.w56Controlled weight reduction in overweight
patients and physical activity have been associated with
improvements in blood pressure, cholesterol, and diabetes. There
are no stroke specific data on dietary modification, although
routine vitamin supplementation probably has no benefit.33
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Additional educational resources
Resources for healthcare professionals
Stroke Association Professional Training (www.stroke.org.uk/professionals/training_and_development/index.html)—
A selection of training and education programmes offered by the stroke association, suitable for all healthcare
professionals
European Stroke Organisation (www.eso-stroke.org)— Comprehensive access to European stroke guidelines and
educational resources for health professionals and lay people
UK Stroke Research Network (www.uksrn.ac.uk)—Provides an infrastructure to facilitate stroke research and improve
communication between academics, stroke clinicians, stroke service users, and research funders
Stroke Training and Awareness Resources (STARS) project (www.stroketraining.org)—Commissioned by the Scottish
Government to provide an e-learning resource for all healthcare professionals and social care staff working with patients
affected by stroke
Resources for patients
The Stroke Association (www.stroke.org.uk)—Produces a number of publications to help educate and inform and
increase awareness of stroke, including patient leaflets, and Stroke News (a quarterly magazine)
Act FAST campaign (www.nhs.uk/actfast/Pages/stroke.aspx)—Public awareness campaign to improve community
recognition of stroke symptoms and encourage those affected to seek urgent medical help
Connect (www.ukconnect.org/index.aspx)—communication disability charity for patients and carers affected by aphasia
Carers UK (www.carersuk.org)—charity providing support for home carers
Tips for non specialists
• Refer all patients with suspected stroke to the local dedicated stroke unit
• Stroke survivors with ipsilateral carotid diseasemay benefit from revascularisation. Outcomes are best when intervention
is performed early; liaise with a vascular multidisciplinary team
• Look out for common post-stroke complications such as infection, delirium, depression, pain, incontinence, and falls
• Treat hypertension aggressively and ensure that patients receive long term thromboprophylaxis
• Consider anticoagulation for all stroke survivors with atrial fibrillation, remembering that age alone is not a
contraindication to anticoagulation
Questions for future research
• What is the optimal model for deep vein thrombosis prophylaxis for patients with ischaemic stroke?
• What is the optimal timing and intensity of multidisciplinary intervention? Can this be targeted?
• Is there a role for screening stroke survivors for common complications; do we have adequate tools to inform a
screening approach?
• Can we develop novel drugs to minimise recurrent disease and provide alternative strategies for intolerant patients;
are novel anticoagulation treatments cost effective?
• What is the role of short duration, high potency antithrombotic therapy following ischaemic stroke?
• What happens to stroke survivors’ functional status in the longer term (years) post-event; is there a role for ongoing
or opportunistic intervention and rehabilitation?
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Tables
Table 1| Potential population impact of acute stroke interventions for a hypothetical population of one million with 2500 strokes per year34
Effectiveness (number of extra
independent survivors†)
Eligibility (proportion stroke
population)
Efficacy (extra independent
survivors (n))*
Treatment
2080%25Aspirin in acute ischaemic stroke
Thrombolysis in ischaemic stroke
2810%280rt-PA within 3 hours
1210%125rt-PA within 3-4.5 hours
10080%125Basic stroke unit care
4235%120Early supported discharge teams and home
rehabilitation
rt-PA=tissue plasminogen activator. Calculations indicate number of extra independent survivors (modified Rankin score 0-2) resulting from an intervention during
a one year period. *Assuming all stroke patients are eligible for treatment. †Taking into account population eligible for treatment.
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Table 2| Summary of patient outcomes in the stroke unit trials3
Extra events per 100 patients (95% CI)Conventional careStroke unitOutcome
5 (1 to 8)*38%44 %Home (independent)
0 (−2 to 3)16%16%Home (dependent)
−2 (−5 to 0)*20%18%Institutional care
−3 (−6 to −1)*26%22%Dead
Proportion (%) of patients with various outcomes at the end of scheduled follow-up (median one year), based on data from Stroke Unit Review (n=6900).
* P<0.05 for difference between groups.
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Table 3| Evidence for antiplatelets in stroke preventionw57-w59
CommentsResult for strokeComparatorAntiplatelet and comparison
AT secondary prevention analysisRR 0.78 95% CI 0.61 to 0.99Placebo>Aspirin
SR (n=23.19 with ischaemic stroke)RR 0.88(95% CI 0.81 to 0.95)Placebo>Dipyridamole
SR 4 RCT (n=1611)RR 0.76 95% CI 0.65 to 0.89Thienopyridines
(clopidogrel)
>Aspirin + dipyridamole MR
SR 4 RCT (n=86 865)OR 0.91, 95% CI 0.84 to 0.98Clopidogrel<Aspirin
RCT (n=20 332)HR 1.01 (95% CI 0.92 to 1.11)Aspirin Aspirin + dipyridamole MR
SR (n=15 603 with risk factors)RR 0.93 (95%CI 0.83 to 1.05) Aspirin + clopidogrel
RCT (n=7599 with risk factors)RRR 6.4% 95% CI −4.6 to 16.3)Clopidogrel  *Aspirin + clopidogrel
On-going multicentre trials––(Aspirin +) dipyridamole +
clopidogrel
Data are for ischaemic stroke secondary prevention unless otherwise stated; references for individual trials and analysis within main body of text.
> indicates greater efficacy than; < indicates lesser efficacy than;   indicates equivalent efficacy; RR=relative risk; OR=odds ratio; HR=hazard ratio; RRR=relative
risk reduction; AT=antiplatelet trialists; SR=systematic review; RCT=randomised controlled trial.
*Increased risk of life threatening or major bleeding seen with addition of aspirin.
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Figure
Components of effective stroke unit care subject to randomised trials (based on Langhorne et al5)
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